EA202090259A1 - NEW HETEROARYLAMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONDEACETHYLASE 1 AND / OR 2 (HDAC1-2) - Google Patents
NEW HETEROARYLAMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONDEACETHYLASE 1 AND / OR 2 (HDAC1-2)Info
- Publication number
- EA202090259A1 EA202090259A1 EA202090259A EA202090259A EA202090259A1 EA 202090259 A1 EA202090259 A1 EA 202090259A1 EA 202090259 A EA202090259 A EA 202090259A EA 202090259 A EA202090259 A EA 202090259A EA 202090259 A1 EA202090259 A1 EA 202090259A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hdac1
- diseases
- new
- selective inhibitors
- histondeacethylase
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 102100039996 Histone deacetylase 1 Human genes 0.000 abstract 2
- 102100039999 Histone deacetylase 2 Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 108010024124 Histone Deacetylase 1 Proteins 0.000 abstract 1
- 108010023981 Histone Deacetylase 2 Proteins 0.000 abstract 1
- 102000003964 Histone deacetylase Human genes 0.000 abstract 1
- 108090000353 Histone deacetylase Proteins 0.000 abstract 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 abstract 1
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 abstract 1
- 206010043391 Thalassaemia beta Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000030761 polycystic kidney disease Diseases 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Изобретение относится к новым гетероариламидным производным формулы (I)как селективным ингибиторам гистондеацетилазы 1 и/или 2 (HDAC1-2), к способам их получения, к фармацевтическим композициям, содержащим указанные соединения, и применению указанных соединений для изготовления лекарственного средства для лечения патологических состояний или заболеваний, которые можно облегчить путем ингибирования активности гистондеацетилазы класса I, в частности HDAC1 и HDAC2, таких как рак, нейродегенеративные заболевания, инфекционные заболевания, воспалительные заболевания, сердечная недостаточность и гипертрофия сердца, диабет, поликистоз почек, серповидно-клеточная анемия и -талассемия, и к способам лечения указанных выше заболеваний.The invention relates to new heteroarylamide derivatives of formula (I) as selective inhibitors of histone deacetylase 1 and / or 2 (HDAC1-2), to methods for their preparation, to pharmaceutical compositions containing these compounds, and the use of these compounds for the manufacture of a medicament for the treatment of pathological conditions or diseases that can be alleviated by inhibiting the activity of class I histone deacetylase, in particular HDAC1 and HDAC2, such as cancer, neurodegenerative diseases, infectious diseases, inflammatory diseases, heart failure and cardiac hypertrophy, diabetes, polycystic kidney disease, sickle cell anemia and β-thalassemia , and to methods of treating the above diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382447 | 2017-07-10 | ||
| PCT/ES2018/070491 WO2019012172A1 (en) | 2017-07-10 | 2018-07-09 | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (hdac1-2) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA202090259A1 true EA202090259A1 (en) | 2020-05-25 |
| EA039144B1 EA039144B1 (en) | 2021-12-09 |
Family
ID=59315557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202090259A EA039144B1 (en) | 2017-07-10 | 2018-07-09 | New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2 (hdac1-2) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11241428B2 (en) |
| EP (1) | EP3653620B9 (en) |
| JP (1) | JP7026787B2 (en) |
| KR (1) | KR102574135B1 (en) |
| CN (1) | CN111051300B (en) |
| AU (1) | AU2018300123B2 (en) |
| BR (1) | BR112020000564A2 (en) |
| CA (1) | CA3069273A1 (en) |
| DK (1) | DK3653620T3 (en) |
| EA (1) | EA039144B1 (en) |
| ES (1) | ES2911040T3 (en) |
| HR (1) | HRP20220472T1 (en) |
| HU (1) | HUE058353T2 (en) |
| LT (1) | LT3653620T (en) |
| MX (1) | MX2020000349A (en) |
| PL (1) | PL3653620T3 (en) |
| PT (1) | PT3653620T (en) |
| RS (1) | RS63156B1 (en) |
| SI (1) | SI3653620T1 (en) |
| WO (1) | WO2019012172A1 (en) |
| ZA (1) | ZA202000727B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114380751A (en) * | 2020-03-30 | 2022-04-22 | 上海辉启生物医药科技有限公司 | Indane amine derivatives, preparation method and application thereof |
| CA3240229A1 (en) | 2021-12-03 | 2023-06-08 | Tango Therapeutics, Inc. | Novel hdac inhibitors and therapeutic use thereof |
| CN114524799B (en) * | 2022-03-11 | 2023-05-26 | 沈阳药科大学 | HDAC inhibitor and preparation method and application thereof |
| EP4306106A1 (en) * | 2022-07-14 | 2024-01-17 | Universidade de Aveiro | Nitro-containing compounds, compositions and uses thereof |
| CN115463215A (en) * | 2022-07-26 | 2022-12-13 | 苏州大学 | New use of HDAC9 and inhibitors thereof |
| WO2024030659A1 (en) | 2022-08-05 | 2024-02-08 | Tango Therapeutics, Inc. | An hdac inhibitor for treating cancer with a modified stk11 activity or expression |
| CN115304513A (en) * | 2022-08-25 | 2022-11-08 | 湖北科技学院 | Chalcone derivative with anti-inflammatory activity and synthesis method and application thereof |
| CN115368277B (en) * | 2022-09-15 | 2024-03-29 | 华侨大学 | Biphenyl compound containing hydroxamic acid structure and application thereof |
| CN116199636A (en) * | 2023-02-21 | 2023-06-02 | 杭州医学院 | 2, 4-disubstituted pyrimidine derivative of targeted tumor immunity kinase, preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090105264A1 (en) * | 2005-11-03 | 2009-04-23 | Christopher Hamblett | Substituted Nicotinamide Compounds |
| WO2007127137A2 (en) * | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
| JP2010531358A (en) * | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | Pyridyl and pyrimidinyl derivatives as histone deacetylase inhibitors |
| MX2011013165A (en) * | 2009-06-08 | 2012-01-30 | Gilead Sciences Inc | Alkanoylamino benzamide aniline hdac inihibitor compounds. |
| CA2963681A1 (en) | 2014-10-08 | 2016-04-14 | Acetylon Pharmaceuticals, Inc. | Induction of gata2 by hdac1 and hdac2 inhibitors |
| AU2016288606A1 (en) * | 2015-07-02 | 2018-01-18 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibtors |
| US9603950B1 (en) * | 2015-10-25 | 2017-03-28 | Institute Of Nuclear Energy Research | Compounds of imaging agent with HDAC inhibitor for treatment of Alzheimer syndrome and method of synthesis thereof |
-
2018
- 2018-07-09 RS RS20220320A patent/RS63156B1/en unknown
- 2018-07-09 KR KR1020207003894A patent/KR102574135B1/en active IP Right Grant
- 2018-07-09 JP JP2020523052A patent/JP7026787B2/en active Active
- 2018-07-09 PL PL18789777T patent/PL3653620T3/en unknown
- 2018-07-09 ES ES18789777T patent/ES2911040T3/en active Active
- 2018-07-09 CA CA3069273A patent/CA3069273A1/en active Pending
- 2018-07-09 HU HUE18789777A patent/HUE058353T2/en unknown
- 2018-07-09 HR HRP20220472TT patent/HRP20220472T1/en unknown
- 2018-07-09 EP EP18789777.2A patent/EP3653620B9/en active Active
- 2018-07-09 US US16/629,457 patent/US11241428B2/en active Active
- 2018-07-09 BR BR112020000564-9A patent/BR112020000564A2/en active Search and Examination
- 2018-07-09 DK DK18789777.2T patent/DK3653620T3/en active
- 2018-07-09 WO PCT/ES2018/070491 patent/WO2019012172A1/en unknown
- 2018-07-09 LT LTEPPCT/ES2018/070491T patent/LT3653620T/en unknown
- 2018-07-09 MX MX2020000349A patent/MX2020000349A/en unknown
- 2018-07-09 CN CN201880056722.5A patent/CN111051300B/en active Active
- 2018-07-09 EA EA202090259A patent/EA039144B1/en unknown
- 2018-07-09 PT PT187897772T patent/PT3653620T/en unknown
- 2018-07-09 AU AU2018300123A patent/AU2018300123B2/en active Active
- 2018-07-09 SI SI201830644T patent/SI3653620T1/en unknown
-
2020
- 2020-02-04 ZA ZA2020/00727A patent/ZA202000727B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200138808A1 (en) | 2020-05-07 |
| JP2020527173A (en) | 2020-09-03 |
| EP3653620B1 (en) | 2022-02-02 |
| HRP20220472T1 (en) | 2022-05-27 |
| ZA202000727B (en) | 2022-07-27 |
| DK3653620T3 (en) | 2022-03-28 |
| KR102574135B1 (en) | 2023-09-01 |
| WO2019012172A1 (en) | 2019-01-17 |
| CN111051300B (en) | 2022-12-23 |
| HUE058353T2 (en) | 2022-07-28 |
| EA039144B1 (en) | 2021-12-09 |
| EP3653620A1 (en) | 2020-05-20 |
| CA3069273A1 (en) | 2019-01-17 |
| LT3653620T (en) | 2022-05-10 |
| KR20200038473A (en) | 2020-04-13 |
| SI3653620T1 (en) | 2022-05-31 |
| MX2020000349A (en) | 2020-08-17 |
| ES2911040T3 (en) | 2022-05-17 |
| CN111051300A (en) | 2020-04-21 |
| PL3653620T3 (en) | 2022-06-20 |
| US11241428B2 (en) | 2022-02-08 |
| AU2018300123B2 (en) | 2022-03-17 |
| RS63156B1 (en) | 2022-05-31 |
| EP3653620B9 (en) | 2022-03-23 |
| AU2018300123A1 (en) | 2020-02-13 |
| JP7026787B2 (en) | 2022-02-28 |
| PT3653620T (en) | 2022-04-22 |
| BR112020000564A2 (en) | 2020-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090259A1 (en) | NEW HETEROARYLAMIDE DERIVATIVES AS SELECTIVE INHIBITORS OF HISTONDEACETHYLASE 1 AND / OR 2 (HDAC1-2) | |
| NZ739026A (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| EA201890618A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF STATES ASSOCIATED WITH ANOMATIC INFLAMMATORY RESPONSES | |
| EA201890338A1 (en) | OXADIAZOLIC DERIVATIVES SUITABLE AS HDAC INHIBITORS | |
| EA201891103A1 (en) | COMPOSITIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | |
| EA201792421A1 (en) | AMIDO-SUBSTITUTED DERIVATIVES OF CYCLOGEXANE | |
| WO2013066839A3 (en) | Compounds and methods | |
| WO2013066835A3 (en) | Compounds and methods | |
| PH12015502425B1 (en) | Novel compounds for selective histone deacetylase inhibitors, and pharmeceutical composition comprising the same | |
| EA201992144A1 (en) | NEW FERROPORTIN SALT INHIBITORS | |
| TR201816176T4 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same. | |
| WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
| MX2020000404A (en) | Syk inhibitors. | |
| EA201492285A1 (en) | COMPOUNDS OF N-ALKYLTRIAZOLE AS ANTAGONISTS OF LYSOPHOSPHATID ACID (LPAR) | |
| EA201591051A1 (en) | ERK INHIBITORS AND THEIR OPTIONS | |
| EA201790599A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS | |
| JO3501B1 (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| WO2014151630A3 (en) | Compounds and compositions for the treatment of parasitic diseases | |
| WO2016004404A3 (en) | Gls1 inhibitors for treating disease | |
| PH12017501823A1 (en) | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same | |
| WO2015187542A8 (en) | Histone deacetylase inhibitors and compositions and methods of use thereof | |
| EA201890532A1 (en) | NEW ANNELED BENZAMIDES | |
| MX2022000945A (en) | Composition for increasing expression of pgc-1î±. | |
| WO2015130790A3 (en) | Salts of heterocyclic modulators of hif activity for treatment of disease | |
| MX362059B (en) | Carbamate/urea derivatives. |